argenx SE

ARGX · NYSE

$873.71−$2.06 (−0.23%)TodayMarket closed · Oct 23, 7:55 PM ET

Prev close $875.76

About ARGX

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. The company is headquartered in Amsterdam, Noord-Holland. The company went IPO on 2014-07-10. The company is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The firm develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. The company includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.

Employees: 1,599
Headquarters: Amsterdam, Noord-Holland
Listed: Jul 10, 2014
Sector: Health Care
Industry: Biotechnology
Website: argenx.com

Leadership

argenx SE executives
Name	Title	Since	Age
Peter Verhaeghe	—	—	65
Tim van Hauwermeiren	—	2008	53
Anthony Rosenberg	—	—	71
Karl Gubitz	—	—	55
Karen Massey	—	—	46
Peter Ulrichts	—	—	45
Arjen Lemmen	—	—	40
Malini Moorthy	—	—	55
Luc Truyen	—	—	60
Andria Wilk	—	—	52
Ana Cespedes	—	—	51
James Daly	—	—	63
Pamela Klein	—	—	63
Brian Kotzin	—	—	76
Steve Krognes	—	—	56
Camilla Sylvest	—	—	52

Similar companies

Companies in the same industry as argenx SE

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.